tradingkey.logo
tradingkey.logo
Search

CNS Pharmaceuticals Inc

CNSP
Add to Watchlist
5.760USD
+0.910+18.76%
Close 07-31 16:00ETQuotes delayed by 15 min
3.64MMarket Cap
LossP/E TTM

CNSP Income Statement

You can find the annual or quarterly income statement of CNS Pharmaceuticals Inc here for insights into the performance and operational efficiency of CNS Pharmaceuticals Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q3
FY2020Q2
FY2020Q1
FY2019Q4
FY2019Q3
FY2019Q2
FY2019Q1
FY2018Q4
FY2018Q3
FY2018Q2
FY2018Q1
Operating expenses
14.70%4.98M
87.06%5.99M
-42.20%3.25M
-4.70%2.41M
22.36%4.34M
-40.51%3.20M
24.15%5.63M
-37.20%2.53M
-28.05%3.54M
-2.23%5.38M
32.61%4.53M
12.93%4.03M
56.44%4.93M
69.21%5.50M
-10.34%3.42M
-6.48%3.56M
-12.76%3.15M
8.33%3.25M
89.62%3.81M
54.07%3.81M
83.41%3.61M
18.94%3.00M
187.67%2.01M
496.00%2.47M
908.83%1.97M
1109.94%2.52M
311.46%699.09K
111.12%415.06K
-36.39%195.09K
--208.58K
--169.91K
--196.60K
--306.70K
R&D expenses
9.28%3.54M
111.27%3.17M
-48.25%2.20M
4.52%1.17M
33.43%3.24M
-64.93%1.50M
24.47%4.24M
-60.76%1.12M
-31.88%2.43M
27.54%4.27M
54.47%3.41M
28.10%2.85M
88.89%3.57M
42.21%3.35M
-14.36%2.21M
-16.65%2.22M
-14.41%1.89M
23.05%2.36M
147.35%2.58M
78.58%2.66M
259.97%2.21M
28.95%1.91M
273.70%1.04M
3392.36%1.49M
1169.13%613.08K
--1.48M
5963.11%278.90K
8765.15%42.73K
198.47%48.31K
--0.00
--4.60K
--482.00
--16.19K
Depreciation, depletion, and amortization
69.82%1.87K
3.55%1.02K
-7.19%697.00
46.41%1.10K
34.47%1.10K
3.36%985.00
-16.46%751.00
-25.02%752.00
-36.04%818.00
-59.97%953.00
-67.82%899.00
-68.71%1.00K
-62.10%1.28K
-31.84%2.38K
-17.07%2.79K
-0.12%3.21K
12.58%3.38K
11.10%3.49K
6.51%3.37K
11.77%3.21K
56.39%3.00K
188.44%3.14K
265.66%3.16K
--2.87K
--1.92K
--1.09K
--865.00
----
----
----
----
----
----
Operating profit
-14.70%-4.98M
-87.06%-5.99M
42.20%-3.25M
4.70%-2.41M
-22.36%-4.34M
40.51%-3.20M
-24.15%-5.63M
37.20%-2.53M
28.05%-3.54M
2.23%-5.38M
-32.61%-4.53M
-12.93%-4.03M
-56.44%-4.93M
-69.21%-5.50M
10.34%-3.42M
6.48%-3.56M
12.76%-3.15M
-8.33%-3.25M
-89.62%-3.81M
-54.07%-3.81M
-83.41%-3.61M
-18.94%-3.00M
-187.67%-2.01M
-496.00%-2.47M
-908.83%-1.97M
-1109.94%-2.52M
-311.46%-699.09K
-111.12%-415.06K
36.39%-195.09K
---208.58K
---169.91K
---196.60K
---306.70K
Net non-operating interest income (expenses)
Non-operating interest income
4.05%44.27K
34.58%35.60K
46.74%37.02K
1992.63%38.61K
532.12%42.55K
277.83%26.46K
95.84%25.23K
-76.35%1.84K
--6.73K
--7.00K
--12.88K
--7.80K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Non-operating interest expense
-1.56%6.11K
-1.91%2.72K
-6.29%2.12K
-6.23%4.18K
-6.29%6.21K
-3.71%2.77K
22.85%2.26K
22.27%4.46K
21.87%6.63K
24.61%2.88K
241.64%1.84K
126.57%3.65K
111.85%5.44K
3.31%2.31K
-43.19%538.00
-31.53%1.61K
-31.52%2.57K
-31.43%2.24K
--947.00
--2.35K
--3.75K
-9.76%3.26K
-100.00%0.00
-100.00%0.00
-100.00%0.00
-74.11%3.62K
-67.55%7.56K
158.82%16.64K
447.40%16.41K
--13.97K
--23.30K
--6.43K
--3.00K
Special income (expenses)
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
100.00%0.00
----
----
----
---6.41M
----
----
----
Other non-operating income (expenses)
----
---2.56K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
--0.00
100.00%0.00
----
--0.00
--0.00
---54.45K
----
Income before tax
-14.78%-4.94M
-87.50%-5.96M
42.59%-3.22M
6.16%-2.37M
-21.34%-4.30M
40.91%-3.18M
-23.95%-5.61M
37.07%-2.53M
28.13%-3.54M
2.34%-5.38M
-32.26%-4.52M
-12.77%-4.02M
-56.48%-4.93M
-69.17%-5.50M
10.35%-3.42M
6.50%-3.57M
12.78%-3.15M
-8.28%-3.25M
-89.67%-3.81M
-54.16%-3.81M
-83.60%-3.61M
-18.90%-3.00M
-184.59%-2.01M
-473.02%-2.47M
-830.55%-1.97M
61.89%-2.53M
-265.76%-706.65K
-67.66%-431.71K
31.71%-211.50K
---6.63M
---193.20K
---257.48K
---309.70K
Income tax
----
----
----
----
----
--0.00
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
----
----
----
----
----
----
----
Income after tax
-14.78%-4.94M
-87.50%-5.96M
42.59%-3.22M
6.16%-2.37M
-21.34%-4.30M
40.91%-3.18M
-23.95%-5.61M
37.07%-2.53M
28.13%-3.54M
2.34%-5.38M
-32.26%-4.52M
-12.77%-4.02M
-56.48%-4.93M
-69.17%-5.50M
10.35%-3.42M
6.50%-3.57M
12.78%-3.15M
-8.28%-3.25M
-89.67%-3.81M
-54.16%-3.81M
-83.60%-3.61M
-18.90%-3.00M
-184.59%-2.01M
-473.02%-2.47M
-830.55%-1.97M
61.89%-2.53M
-265.76%-706.65K
-67.66%-431.71K
31.71%-211.50K
---6.63M
---193.20K
---257.48K
---309.70K
Net income from continuous operations
-14.78%-4.94M
-87.50%-5.96M
42.59%-3.22M
6.16%-2.37M
-21.34%-4.30M
40.91%-3.18M
-23.95%-5.61M
37.07%-2.53M
28.13%-3.54M
2.34%-5.38M
-32.26%-4.52M
-12.77%-4.02M
-56.48%-4.93M
-69.17%-5.50M
10.35%-3.42M
6.50%-3.57M
12.78%-3.15M
-8.28%-3.25M
-89.67%-3.81M
-54.16%-3.81M
-83.60%-3.61M
-18.90%-3.00M
-184.59%-2.01M
-473.02%-2.47M
-830.55%-1.97M
61.89%-2.53M
-265.76%-706.65K
-67.66%-431.71K
31.71%-211.50K
---6.63M
---193.20K
---257.48K
---309.70K
Net income attributable to controlling interests
-14.78%-4.94M
-87.50%-5.96M
42.59%-3.22M
6.16%-2.37M
-21.34%-4.30M
40.91%-3.18M
-23.95%-5.61M
37.07%-2.53M
28.13%-3.54M
2.34%-5.38M
-32.26%-4.52M
-12.77%-4.02M
-56.48%-4.93M
-69.17%-5.50M
10.35%-3.42M
6.50%-3.57M
12.78%-3.15M
-8.28%-3.25M
-89.67%-3.81M
-54.16%-3.81M
-83.60%-3.61M
-18.90%-3.00M
-184.59%-2.01M
-473.02%-2.47M
-830.55%-1.97M
61.89%-2.53M
-265.76%-706.65K
-67.66%-431.71K
31.71%-211.50K
---6.63M
---193.20K
---257.48K
---309.70K
Net income attributable to common shareholders
-14.78%-4.94M
-87.50%-5.96M
42.59%-3.22M
6.16%-2.37M
-21.34%-4.30M
40.91%-3.18M
-23.95%-5.61M
37.07%-2.53M
28.13%-3.54M
2.34%-5.38M
-32.26%-4.52M
-12.77%-4.02M
-56.48%-4.93M
-69.17%-5.50M
10.35%-3.42M
6.50%-3.57M
12.78%-3.15M
-8.28%-3.25M
-89.67%-3.81M
-54.16%-3.81M
-83.60%-3.61M
-18.90%-3.00M
-184.59%-2.01M
-473.02%-2.47M
-830.55%-1.97M
61.89%-2.53M
-265.76%-706.65K
-67.66%-431.71K
31.71%-211.50K
---6.63M
---193.20K
---257.48K
---309.70K
Basic earnings per share
-362.84%-7.30
-16.76%-9.70
54.43%-5.76
98.09%-6.42
99.84%-1.58
99.69%-8.31
99.53%-12.64
87.04%-335.96
84.27%-1.02K
71.51%-2.64K
57.75%-2.71K
61.19%-2.59K
-6.18%-6.47K
-5.80%-9.27K
38.54%-6.41K
40.59%-6.68K
44.56%-6.09K
-79.07%-8.77K
-13.93%-10.42K
0.29%-11.25K
-22.45%-10.99K
61.07%-4.90K
-134.34%-9.15K
-284.41%-11.28K
-788.86%-8.97K
20.69%-12.58K
-182.78%-3.90K
-138.68%-2.93K
31.71%-1.01K
---15.86K
---1.38K
---1.23K
---1.48K
Diluted earnings per share
-362.84%-7.30
-16.76%-9.70
54.43%-5.76
98.09%-6.42
99.84%-1.58
99.69%-8.31
99.53%-12.64
87.04%-335.96
84.27%-1.02K
71.51%-2.64K
57.75%-2.71K
61.19%-2.59K
-6.18%-6.47K
-5.80%-9.27K
38.54%-6.41K
40.59%-6.68K
44.56%-6.09K
-79.07%-8.77K
-13.93%-10.42K
0.29%-11.25K
-22.45%-10.99K
61.07%-4.90K
-134.34%-9.15K
-284.41%-11.28K
-788.86%-8.97K
20.69%-12.58K
-182.78%-3.90K
-138.68%-2.93K
31.71%-1.01K
---15.86K
---1.38K
---1.23K
---1.48K
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read CNS Pharmaceuticals Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing CNSP stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was CNS Pharmaceuticals Inc's net income for the year?

CNS Pharmaceuticals Inc posted -15.85M in net income for fiscal year 2025.

How much net income did CNS Pharmaceuticals Inc post in the last quarter?

CNS Pharmaceuticals Inc reported -4.94M in net income for the latest quarter。

What was CNS Pharmaceuticals Inc's annual operating profit?

CNS Pharmaceuticals Inc's operating income was -15.99M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.